Overview

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

Status:
NOT_YET_RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Evaluating Bemotuzumab to improve the efficacy of neoadjuvant chemotherapy for Triple-Negative Breast Cancer (TNBC)
Phase:
NA
Details
Lead Sponsor:
Zhejiang Provincial People's Hospital
Treatments:
130-nm albumin-bound paclitaxel
Carboplatin
Cyclophosphamide
Epirubicin